In a recent development, pharmaceutical giant Pfizer has accused Moderna of providing inconsistent information to the U.S. Food and Drug Administration (FDA) and the Patent Trial and Appeal Board (PTAB) in defense of its COVID-19 vaccine patents. According to Pfizer, the language Moderna used to swiftly procure FDA approval of its COVID-19 vaccines should jeopardize its attempts to uphold its patents at the board.
Pfizer claims that Moderna is practicing a “litigation-driven one-eighty,” an accusation suggesting that Moderna has taken contradictory stances in different judicial arenas for strategic reasons. This situation underscores the tension and competitive atmosphere that often characterize the pharmaceutical industry, particularly when billion-dollar patents are at stake.
While legal professionals worldwide will be watching the situation between Moderna and Pfizer closely, affording a clear insight into this case necessitates a closer examination of the precise language and legal maneuvers employed by Moderna both at the FDA and PTAB. For details and further updates on this ongoing legal drama, you can refer to an article on Law360 .